Evidence map›Paper›PMID 19026770›Full record

ReviewBiochimica et biophysica acta2009

Mechanisms of RND multidrug efflux pumps.

Hiroshi Nikaido, Yumiko Takatsuka

Open access · greenAbstract readReview
In one paragraph

Review in Biochimica et biophysica acta, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 257 papers.

0numbers the graph read from it
0cells of the map it votes in
257citing papers in PubMed
8.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

257 citing papers in PubMed, 547 citations in OpenAlex.

  1. High resolution cryo-EM structure of theJournal of structural biology: X · 2026
    Article
  2. Article
  3. Review
  4. Antimicrobial efficacy of carbon nanotube-based nano drug onBiochemistry and biophysics reports · 2026
    Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. A rational approach to discovering new persister control agents.Antimicrobial agents and chemotherapy · 2025
    Article
  14. JAC-antimicrobial resistance · 2025
    Article
  15. Article
  16. CombattingAntibiotics (Basel, Switzerland) · 2025
    Review
  17. Article
  18. Article
  19. Article
  20. Article

197 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Hiroshi NikaidoDepartment of Molecular and Cell Biology, Barker Hall, University of California, Berkeley, CA 94720-3202, USA. nhiroshi@berkeley.edu
Yumiko Takatsuka
University of California, Berkeley · US

Funding

BIOCHEMISTRY OF BACTERIAL CELL MEMBRANESR01AI009644 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI NIKAIDO, HIROSHI · 1985 to 2015
$9.7M
BIOCHEMISTRY OF BACTERIAL CELL MEMBRANESR37AI009644 · NIAID · UNIVERSITY OF CALIFORNIA BERKELEY · PI NIKAIDO, HIROSHI · 1991 to 2000
$467k
NIAID NIH HHS AI 09644NIAID NIH HHS R01 AI009644NIAID NIH HHS R37 AI009644
6 · The paper itself

Abstract

RND (Resistance-Nodulation-Division) family transporters are widespread especially among Gram-negative bacteria, and catalyze the active efflux of many antibiotics and chemotherapeutic agents. They have very large periplasmic domains, and form tripartite complexes with outer membrane channels and periplasmic adaptor proteins. AcrAB-TolC complex of Escherichia coli, which pumps out a very wide range of drugs, has been studied most intensively. Early studies showed that the transporter captures even those substrates that cannot permeate across the cytoplasmic membrane, such as dianionic beta-lactams, suggesting that the capture can occur from the periplasm. It was also suggested that the capture occurs from the cytoplasmic membrane/periplasm interface, because most substrates contain a sizable hydrophobic domain; however, this may simply be a reflection of the nature of the binding site within AcrB. Genetic studies of chimeric transporters showed that much of the substrate specificity is determined by their periplasmic domains. Biochemical studies with intact cells recently led to the determination of the kinetic constants of AcrB for some beta-lactams, and the result confirms the old prediction that AcrB is a rather slow pump. Reconstitution of purified AcrB and its relatives showed that the pump is a drug/proton antiporter, that AcrA strongly stimulates the activity of the pump, and that AcrB seems to have a highest affinity for conjugated bile salts. Structural study with mutants of the network of charged residues in the transmembrane domain showed that protonation here produced a far-reaching conformational change, which was found to be present in one of the protomers in the asymmetric crystal structure of the wild-type AcrB. The functional rotatory hypothesis then predicts that the drug bound in the periplasmic domain is extruded through this conformational change initiated by the protonation of one of the residues in the aforementioned network, an idea that was recently supported by disulfide cross-linking as well as by the behavior of linked AcrB protomers.

Indexed as

ATP-Binding Cassette, Sub-Family C ProteinsBacterial ProteinsCarrier ProteinsCrystallography, X-RayDrug Resistance, BacterialEscherichia coli ProteinsKineticsModels, MolecularMutagenesis, Site-DirectedMutationPhospholipidsAcrAB-TolC protein, Salmonella entericaAcrB protein, E coliATP-Binding Cassette, Sub-Family C ProteinsBacterial ProteinsCarrier ProteinsEscherichia coli ProteinsPhospholipids

Identifiers

PMID19026770
PMCPMC2696896
OpenAlexW1964509770

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.